DOSE-DEPENDENCE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]-PYRIDINE (PHIP) CARCINOGENICITY IN RATS

DOSE-DEPENDENCE OF 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]-PYRIDINE (PHIP) CARCINOGENICITY IN RATS
复制标题

DOI:
10.1093/carcin/14.12.2553
复制
发表时间:
1993-12-01
期刊:
影响因子:
4.7
通讯作者:
ITO, N
ITO, N
中科院分区:
医学2区
文献类型:
--
作者:
HASEGAWA, R;SANO, M;ITO, N

文献摘要

被引文献

相似文献

在饮食中以 25 或 100 p.p.m. 的浓度给予标题杂环胺的 F344 雌性大鼠中,研究了 2-氨基-1-甲基-6-苯基咪唑-[4,5-b]吡啶 (PhIP) 致癌性的剂量依赖性。长达 104 周。下午 25 点,乳腺癌的发病率为 7% (2/30)。下午 100 点为 47%(30 只老鼠中的 14 只)在 100 p.p.m. 的研究中,女性和结肠腺癌的发病率分别为男性 43% (13/30) 和女性 13% (4/30)。组。下午 25 点,男性中没有诱发乳腺癌,也没有观察到结肠癌。任何性别的群体。此外,PhIP 明显促进了男性淋巴细胞白血病的发展。在一项单独的实验中,在以 25、100 或 400 p.p.m 的剂量喂食添加 PhIP 的饮食 8 周后,大肠中异常隐窝(被认为是肿瘤前病变)的剂量依赖性诱导很明显。因此,结肠癌和乳腺癌的发生都表现出明显的剂量依赖性。由于 PhIP 是一种特别丰富的杂环胺,其致癌性器官倾向与西方国家最常见的肿瘤类型重叠,因此该化合物可能对人类癌症的发展极为重要。
The dose-dependence of 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) carcinogenicity was investigated in F344 rats of both sexes administered title heterocyclic amine in the diet at concentrations of 25 or 100 p.p.m. for up to 104 weeks. Incidences of mammary adenocarcinomas were 7% (2/30) for 25 p.p.m. and 47% (14 of 30 rats) for 100 p.p.m. in females and those of colon adenocarcinomas were 43% (13/30) for males and 13% (4/30) for females of the 100 p.p.m. groups. No mammary adenocarcinomas were induced in males and no colon carcinomas were observed in the 25 p.p.m. groups of either sex. Furthermore, development of lymphocytic leukemia was apparently enhanced by PhIP in males. In a separate experiment, dose-dependent induction of aberrant crypts in the large intestine, considered as preneoplastic lesions, was evident after 8 weeks feeding of PhIP-supplemented diet at doses of 25, 100 or 400 p.p.m. Thus a clear dose-dependency was demonstrated for both colon and mammary carcinogenesis. Since PhIP is a particularly abundant heterocyclic amine and its carcinogenic organotropism overlaps with the types of neoplasias most commonly observed in western countries, the compound may be extremely important with respect to human cancer development.